The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
The latest on manufacturing and potential treatments for COVID-19 with news from Novartis, the National Institutes of Health, Gilead, GSK, Congress, Inovio, and Cipla.
News from Novartis, NIH, Gilead, GSK, Congress
Novartis Discontinues Trial of...
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), led by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by...
A roundup of news from Japan (Takeda), the Netherlands (Gilead Sciences) and the US (GSK, Amarin, Apotex).
Japan
Takeda Receives FDA Warning Letter Takeda has received a Warning Letter from the US Food and Drug Administration (FDA) for GMP...
Eli Lilly and Company and Evox Therapeutics, an Oxford, UK-headquartered biopharmaceutical company, have entered into a research collaboration and license agreement, in a deal worth up to $1.5 billion, to develop and deliver RNA interference (RNAi)...
Takeda and Neurocrine Biosciences, a San Diego, California-based pharmaceutical company developing small molecules for neurological and endocrine-related disorders, have entered into a strategic collaboration, in a deal worth up to $2.015 billion,...
Sanofi plans to invest EUR 610 million ($685 million) to create a new production site and research center for vaccines in France, including to allow it to respond to future pandemic risks.
In keeping with a corporate strategy announced last...
The US Food and Drug Administration (FDA) has revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate to be used to treat certain hospitalized patients with COVID-19 when a...
The latest on manufacturing and potential treatments for COVID-19 with news from Lilly, Gilead, Dr. Reddy’s, Daiichi Sankyo, BioNTech, CureVac, Novavax and others.
News from Lilly, Dr. Reddy’s, Gilead, Daiichi Sankyo
Lilly Begins Phase III Trial...
Five companies—Teva Pharmaceuticals USA, Lupin, Apotex, Anmeal Pharmaceuticals and Marksans Pharma—are voluntarily recalling in the US select lots of metformin extended-release formulations, a drug to treat Type 2 diabetes, due to evaluated levels...
The European Commission (EC) has granted approval of Elanco Animal Health’s pending $7.6- billion acquisition of Bayer AG’s animal health business. The companies announced the acquisition last year (August 2019) and now anticipate a closing early...
Roche and Innovent Biologics, a Suzhou, China-based biopharmaceutical company, have entered into a strategic research and development collaboration in a deal worth up to $2.1 billion (exercise payments totaling $140 million plus milestone...
AstraZeneca and Accent Therapeutics, a Lexington, Massachusetts-based biopharmaceutical company developing oncology-focused, small molecule therapies, have formed a deal, worth up to $1.1 billion ($55 million up front and $1.1 billion in additional...
AbbVie and Genmab, a biopharmaceutical company specializing in antibody therapeutics for treating cancer, have signed a broad collaboration agreement, worth up to $3.9 billion ($750 million up front with the potential to earn $3.15 billion in...
A roundup of news from Denmark (Lundbeck), Japan (Takeda), and the US (UCB).
Denmark
Lundbeck to Cut R&D Staff H. Lundbeck A/S, a Valby, Denmark biopharmaceutical company, is reorganizing its R&D-organization that may result in cut staff...
The latest on manufacturing and potential treatments for COVID-19 with news from Moderna, J&J, Lilly, AbbVie, Novavax, Daiichi Sankyo, CSL, and AstraZeneca.
Moderna Advances Late-Stage Development of COVID-19 Vaccine Moderna, a clinical-stage...
